A Comparison of Efficacy and Safety of Fractional Carbon Dioxide Laser and Fractional Er:YAG Laser for the Treatment of Xanthelasma Palpebrarum: A Two-Center Randomized Split-Face Controlled Trial.

Xanthelasma palpebrarum (XP) is a form of cutaneous xanthoma that presents as collections of yellowish papules or plaques around the eyelids or canthus, affecting patients cosmetically. This study aimed to compare the efficacy and safety of fractional carbon dioxide (CO) laser to that of fractional Er:YAG laser for the treatment of XP. Two centers recruited patients diagnosed with XP of bilaterally symmetrical lesions. The lesion on one side was randomly assigned to be treated with fractional CO laser while the lesion on the other side was treated with fractional Er:YAG laser. All subjects received up to five treatments, with a 4-week interval between each treatment. Thirty-nine patients completed the study and a total of 82 lesions were available for final assessment. The percentage of "Excellent Improvement" on third and fourth visit was 60.98% versus 39.02% and 90.24% versus 63.41%, respectively,  < 0.05. In a follow-up for 12 to 25 months, the number of lesions recurred on the side treated with fractional CO laser and fractional Er:YAG laser are 9 (22%) and 10 (24%), respectively. In this study, fractional CO laser therapy appears superior since a fewer treatments are required for patients to show significant clinical improvement.